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Abstract
Background: Li-Fraumeni Syndrome (LFS) is a cancer predisposition syndrome characterized by the early-onset of
multiple primary cancers which can occur at different moments (metachronous onset) or, more rarely,
coincidentally (synchronous onset). Here we describe a previously unreported patient with presentation of
synchronous Wilms tumor and Choroid plexus papilloma, leading to the diagnosis of a Li-Fraumeni Syndrome (LFS).
Case presentation: A 6-year-old girl without previous complains presented with abdominal pain. Abdominal US
and MRI showed a left renal tumor with subcapsular hematoma. Due to mild headaches, the diagnostic workup
included a brain MRI that unexpectedly identified a large left parietal lobe tumor. Histopathological analysis
determined the diagnosis of classic Wilms tumor and choroid-plexus papilloma (CPP), respectively. Both neoplasms
showed intense nuclear p53 immunostaining associated with the pathogenic TP53 mutation c.844C > T
(p.Arg282Trp). Our patient and her father shared the same heterozygous germline TP53 mutation, confirming the
diagnosis of familiar Li-Fraumeni syndrome in the girl. The treatment was tailored to simultaneous tumor
presentations.
Conclusions: LFS has been associated with Choroid plexus carcinoma (CPC), but rarely with CPP as in our patient.
That suggests that it may be advisable to consider the possibility of analyzing TP53 mutation, not only in all
patients with CPC, but also in some patients with CPP, especially when histological or clinical evidences point out
to perform this study. The dissimilar presentation of LFS among our patient’s father, not having so far any neoplasia
diagnosed, while her daughter presented precociously with two simultaneous different tumors, could be related to
possible effects of modifier genes on the underlying mutant p53 genotype.
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Background
The presentation of two or more different neoplasias in
the same patient is an unusual situation that suggests an
underlying cancer predisposition condition. Li-Fraumeni
Syndrome (LFS) is a cancer predisposition syndrome
characterized by the early-onset of multiple primary can-
cers such as breast cancer, soft tissue and bone sarco-
mas, brain tumors and adrenal cortical carcinoma
(ACC) [1]. The diagnosis of multiple cancers can occur
at different moments (metachronous onset) or, more
rarely, coincidentally (synchronous onset) [2]. Here we
report a patient with synchronous Wilms tumor and
Choroid plexus papilloma (CPP) leading to the diagnosis
of a Li-Fraumeni Syndrome (LFS), situation that has not
been described so far in the literature.
Case presentation
A 6-year-old girl patient presented to the ER (emergency
room) with an intense abdominal pain accompanied by
pallor, vomiting, sweating and hematuria. The abdom-
inal ultrasound revealed the presence of a nodular lesion
in the left kidney and local hemorrhage. Her medical
history was unremarkable except for occasional self-
limited episodes of mild headache. She had normal de-
velopmental milestones, a satisfactory school perform-
ance and brisk dancing skills. Some family members
were diagnosed with carcinomas, all with adult-onset. At
admission, her physical examination was remarkable for
abdominal tenderness without any evident neurological
deficits. The abdominal CT scan ruled out acute arterial
bleeding and an MRI confirmed a tumor in the upper
pole of the left kidney with extensive intracapsular
hemorrhage, suggestive of a Wilms’ tumor (Fig. 1 panel
a). Due to the episodes of headache, the initial workup
was extended with a brain MRI that the presence of a
fairly large left supratentorial tumor with high cellularity
and vascularization, features suggestive of high-grade
neoplasia (Fig. 1 panel b). There was no evidence of
leptomeningeal, lung, or systemic dissemination. Deeper
neurological examination revealed full right hemianopia,
which had been detected to that moment.
Since the renal hemorrhage improved spontaneously
during the initial evaluation period, the cerebral tumor
surgery was prioritized. The initial neurosurgery could
only achieve a partial resection due to the high vascular-
ity and extremely hard texture of the tumor, requiring
intraoperative transfusional support. Postoperative
hydrocephalus required a ventriculo-peritoneal shunt.
The CT scan after the shunt procedure showed a highly
calcified tumor (Fig. 1, panel c). The histological analysis
identified a choroidal plexus tumor composed of well-
differentiated papillary pattern covered by cells with nu-
clear pleomorphism and cytological atypia, but no evi-
dence of solid pattern, mitotic figures or necrosis were
identified (supplementary material). Intense p53 nuclear
staining was identified by immunohistochemistry (IHC)
in the near-totality of cells. The Ki67 stain was positive
in less than 10% of cells. The histopathological diagnosis
was plexus papilloma with atypical features. However,
due to difficulty in evaluation of the grade of this tumor,
an international review was requested which confirmed
the diagnosis of a typical choroid plexus papilloma
Fig. 1 Radiological studies. Panel a Intravenous contrast-enhanced abdominal CT, coronal view: a solid, heterogeneous tumor in the upper pole
of the left kidney is identified (upper, thin arrow), with an adjacent subcapsular perirenal hematoma (lower, thick arrow). The actual diameters
were 36 mm× 28mm× 27mm in anteroposterior, transverse, and craniocaudal planes. Panel b Cerebral MRI, T2-weighted sequence, axial view. A
solid supratentorial intraventricular tumor with left parietal lobe extension is shown. Cystic areas in the basal peripheral and medial aspects are
identified .The tumor causes localized ventriculomegaly, vasogenic edema and midline shift. The actual diameters (tumor and cysts) were 81 ×
59 × 75 mm in the anteroposterior, transverse, and craniocaudal planes. Panel c Non-enhanced Brain CT scan after shunt insertion. Axial
reconstruction. A left parietal tumor with extensive calcification is shown. Ventricular catheter tip is in the right frontal ventricular horn
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(CPP) (Dr. Martin Hasselblat, international CPT registry
[3] also see acknowledgments-. Sanger sequencing of
TP53 (NM_000546.6) identified in the CPP the missense
variant c.844 C > T (p.Arg282Trp), previously reported
as a pathogenic/likely pathogenic mutation
(COSM10704; dbSNP variant rs28934574). The wild-
type allele was absent, consistent with the loss of hetero-
zygosity (Fig. 2). Germline TP53 mutation analysis was
performed. Sanger sequencing revealed the presence of
the c.844C > T mutation in heterozygous status in the
patient’s peripheral blood. Informed consent signed by
parents was obtained before germline testing. Our find-
ings confirmed the suspected Li–Fraumeni syndrome as
the cancer predisposition syndrome underlying the pa-
tient’s malignancies (Fig. 2). Genetic testing of the family
disclosed that she shared with her healthy father the
Fig. 2 Findings from the molecular genetic analysis of TP53 gene in patient’s tissues. Sanger sequencing. From top to bottom traces show wild-
type control DNA, patient’s CPP DNA, Wilms tumor DNA, both carrying the pathogenic TP53 mutation in homozygous status consistent with the
absence of the wild type allele, and in the lower trace the heterozygous germline TP53 mutation. The TP53 missense mutation in exon 8
(c.844C > T; p.R282W; CGG > TGG) is marked in yellow
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same TP53 mutation, while both, her mother and sister,
had no deleterious variants.
After the first neurosurgery, the administration of a
course of ICE chemotherapy (Ifosfamide-carboplatin-
etoposide) [4] was given to facilitate a second look sur-
gery, but also considering that would be useful for both
the choroid plexus tumor and the likely concomitant
Wilms tumor. After one ICE Course the MRI evaluation
showed that the cerebral tumor was stable, whereas the
renal tumor was slightly reduced and the pericapsular
hematoma was completely resolved. Before the second
neurosurgery a cerebral arteriography was performed
without detecting any actively dependent vessels, there-
fore tumor embolization was not performed. In the sec-
ond neurosurgery only partial resection could be
accomplished because of hemodynamic instability due to
hemorrhage. The histopathological analysis confirmed
CPP with atypical features and prominent osseous and
cartilaginous metaplasia. The residual tumor caused par-
tial exclusion on the left lateral ventricle. An Ommaya-
type reservoir with the catheter tip implanted into the
excluded ventricle permitted withdrawal of CSF and re-
solved the symptoms of the segmental ventriculomegaly.
After confirming the stability of the cerebral tumor,
complete resection was deferred in order to focus on the
renal tumor. A radical left nephrectomy showed a Stage
II Wilms’ tumor without anaplasia, but nuclear unrest
was patent; p53 IHC staining was very strong and Sanger
sequencing of TP53 demonstrated the presence of the
same homozygous c.844C > T mutation identified in the
CPP tumor (Fig. 2). Chromosomal analysis (CytoScan
HD Array, ThermoFisher Scientific) of the Wilms’ tumor
revealed a complex pattern of copy-number gains and
losses affecting numerous chromosomes (Supplementary
Figure C). Chromosome 17 displayed two chromosomal
abnormalities, a long contiguous region of absence of
heterozygosity encompassing the entire short arm of
chromosome 17 associated with an extra copy of the en-
tire chromosome (trisomy). The short arm of chromo-
some 17 displayed thus three homozygous, uniparental
copies. More than 70% of the viable tumor consisted of
blastema. Chemotherapy was tailored to the blastemal-
type Wilms tumor and the persistent CPP, with alternat-
ing cycles of VAD chemotherapy (Vincristine / Actino-
mycin / Doxorubicin) [5] with ICE, for four courses.
Although the role of adjuvant chemotherapy is contro-
versial in CPP, the aim of the treatment was to facilitate
the surgical resection [6]. At the end of chemotherapy
the patient underwent a third intervention for the brain
tumor and a complete resection was achieved with an
uneventful postoperative course. The histology con-
firmed CPP.
At the time of this report, more than 2 years follow-up
after diagnosis, the patient is in complete remission with
no new tumors identified during the follow-up. So far,
her father has regular follow-up examination and has
not been diagnosed with any type of neoplasia.
Discussion
Li-Fraumeni syndrome (LFS) is a cancer predispos-
ition syndrome caused by heterozygous germline mu-
tations in the TP53 tumor suppressor gene on
chromosome 17p13.1 (LFS, OMIM# 151623) [7]. The
mutation may be inherited from one of the parents
with an autosomal dominant manner or may be due
to a spontaneous (de novo) genetic mutation. TP53 is
a key regulator of cell cycle checkpoints and apop-
tosis. Upon activation by cellular stress, particularly
DNA damage, p53 binds DNA and induces the tran-
scription of downstream genes involved in apoptosis,
cell cycle arrest and DNA repair [8]. Somatic muta-
tions in the TP53 gene are one of the most frequent
alterations identified in sporadic human cancer.. The
p.Arg282Trp mutation diagnosed in our patient in-
volves a recognized “hot-spot” residue in p53’s DNA-
binding domain, among the most common TP53
mutations in human cancers [9], and has been previ-
ously described associated with early onset of familial
cancers [10].
The spectrum of LFS neoplasias includes typically pre-
menopausal breast cancers, soft tissue sarcomas, brain
tumors and adrenocortical carcinomas (ACC) [1, 2, 11,
12]. Unlike in adults with LFS, children can also develop
typical “pediatric” embryonal tumors [11, 13, 14]. The
most frequent neoplasias associated to LFS in pediatric
age are osteosarcoma, rhabdomyosarcoma, low hypodip-
loid leukemia [14], ACC, choroidal plexus carcinomas
(CPC), SHH medulloblastomas [15], likewise Wilms
tumor or neuroblastoma have also been reported. Chor-
oid plexus tumors represent only 3% of pediatric brain
tumors. There are three histologic variants: papillomas,
atypical papillomas, and carcinomas. The CPPs outnum-
ber CPCs by a ratio of at least 5: 1 [3, 16]. While the as-
sociation of CPC with the Li-Fraumeni Syndrome is well
known, the association with CPP is very rare [17, 18].
Here, we report a patient with synchronous Wilms
tumor and choroid plexus papilloma (CPP). It is of inter-
est that LFS has been associated with CPC, but not with
CPP as in our patient. Based on these findings, it may be
advisable to consider the possibility of analyzing TP53
mutation, not only in all patients with CPC, but also in
some patients with CPP, especially when histological or
clinical evidences point out to perform this study .
The management of neoplasias in the context of a LFS
should be planned with a curative intent although the
prognosis in some instances can be worse [14, 15]. Local
therapy with surgery without irradiation stands as a
mainstay element of therapy because these patients have
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an increased risk of developing secondary neoplasm after
radiation therapy, therefore the recommendation is to
avoid it if possible, especially when the tumor is likely to
be locally controlled by surgery only [19–21]. Synchron-
ous neoplasia in our case added diverse challenges to ad-
just the chronology of surgeries and the
chemotherapeutic schema. Fortunately, according to
histological or staging features both tumors were not
candidate to radiation therapy. Moreover, as soon as the
LFS was diagnosed in our patient, the use of CT scans
and radiologic ionizing procedures was limited to pre-
vent ionizing damage, e.g., performing one short MRI se-
quence in case of suspicion of shunt dysfunction instead
of CT.
The diagnosis of LFS, with constitutional TP53 muta-
tion can be suggested either by the characteristics of the
first tumor, the identification of a second tumor as in
our case, or else by performing familial genetic studies
after an index case is diagnosed. Germline TP53 muta-
tion testing recommendation have been summarized in
the Chompret Criteria updated as the following: 1) After
familial presentation of a proband with a LFS spectrum
tumor prior to age 46 years and at least one first- or
second-degree relative with a LFS tumor before the age
of 56 years or with multiple tumors, 2) In the case of
multiple malignancies and 3) In rare tumors as ACC,
choroid plexus carcinoma or embryonal anaplastic sub-
type rhabdomyosarcoma or 4) Breast cancer before age
31 years [22].
The evaluation of TP53 gene status has important
clinical implications for surveillance due to a high risk of
developing cancer during lifetime. The risk of developing
tumors is as high as 70% and the cumulative probability
of a second cancer is 57% (± 10%) at 30 years. The use
of a complete clinical surveillance protocol with labora-
tory tests and imaging such as whole-body MRI has
allowed the early detection of asymptomatic tumors in
TP53 mutations carriers, leading to an improved long-
term survival [20–23].
Although our patient’s father harbored the same
pathogenic germline mutation (p.Arg282Trp), he has not
developed so far any neoplasia, while her daughter pre-
sented with two simultaneous tumors at early age of on-
set.. The p.Arg282Trp mutation has been reported as a
hotspot variant at both germline and somatic levels asso-
ciated with poorer prognosis as compared to other
pathogenic missense variants [24]. Recent studies have
described a potential gain of function effect of the
p.Arg282Trp mutant, however further studies are
needed to define the mechanisms through which this
mutant protein affects the p53 signaling pathway. How-
ever, the heterogeneous and complex phenotype of LFS
observed amongst affected family members is not readily
explained by the unique identification of germline TP53
mutations; this variability in age of onset and tumor his-
totypes among affected individuals has been related to
possible effects of modifier genes on the underlying mu-
tant p53 genotype [10, 11, 25]. And also to a genetic an-
ticipation with late cancer onset [26]. Furthermore,
diverse studies have revealed that p53 mutations are bio-
logically distinct. The same germline TP53 mutation
may have different functional consequences in different
tissue types. Alongside with the TP53 mutation, the
order in which additional genetic alterations occur may
collaboratively contribute and impact the timing and de-
velopment of tumors [27].
Conclusions
We report a new familial LFM patient with an unre-
ported synchronous Wilms tumor and Choroid plexus
papilloma. This is remarkable as that LFS has been asso-
ciated with Choroid plexus carcinoma (CPC), but rarely
with CPP as in our patient. That suggests that it may be
advisable to consider the possibility of analyzing TP53
mutation, not only in all patients with CPC, but also in
some patients with CPP, especially when histological or
clinical evidences point out to perform this study may
be analyzed not only in CPC, but also in CPP. On the
other hand our patient’s father, harboring the same
pathogenic germline mutation, has not developed so far
any neoplasia, while her daughter presented with two
simultaneous tumors at early age of onset. The heteroge-
neous phenotype of LFS observed amongst affected fam-
ily members could be related to possible effects of
modifier genes on the underlying mutant p53 genotype,
or to a genetic anticipation, and this could explain the
phenotypical differences between our patient’s father
and her daughter.
Supplementary Information




ACC: Adrenocortical carcinoma; CPC: Choroid plexus carcinoma;
CPP: Choroid plexus papilloma; CPT registry: Choroid plexus tumors registry;
CT: Computerized tomography; CSF: Cerebrospinal fluid; ER: Emergency
room; ICE: Ifosfamide Carboplatin Etoposide; IHC: Immunohistochemistry;
LFS: Li Fraumeni Syndrome; MRI: Magnetic resonance imaging;
VAD: Vincristine-Actinomycin-Doxorubicin; US: Ultrasound; WT: Wilms Tumor
Acknowledgements
The authors thank the multidisciplinary team of our institution for their
valuable work and support with this patient.
We thank Dr. Martin Hasselblatt and Dr. Uwe Kordes from the International
Choroid Plexus Registry (International CPT-SIOP-Registry, www.uke.de/cpt),
for their histological review and insights about the brain tumor.
Cruz et al. Hereditary Cancer in Clinical Practice            (2021) 19:1 Page 5 of 6
Authors’ contributions
OC and VC wrote the manuscript. CL established and performed the
molecular assays. MS performed the histological examination of the tumors.
JM reviewed the radiological data. All the authors participated in the
diagnosis, medical or surgical treatment and follow-up of the reported pa-
tient. All the authors contributed with revisions and approved the final ver-
sion of the manuscript.
Funding
This manuscript was completed without any sources of funding.
Availability of data and materials
Most data generated or analyzed during this study are included in this
published article and its supplementary information files. Complete datasets
generated and/or analyzed are not publicly available due to individual
privacy could be compromised, but are available from the corresponding
author on reasonable request.
Ethics approval and consent to participate
Parents gave written informed consent for tumor collection and genetic
studies. A copy of the written consent is available for review on request.
Consent for publication
Parents gave written informed consent for the publication of data and
images from this case report. A copy of the written consent is available for
review on request.
Competing interests
The authors declare that they have no competing interests.
Author details
1Department of Pediatric Oncology, Hospital Sant Joan de Déu, Esplugues de
Llobregat, Passeig Sant Joan de Deu 2, 08950 Barcelona, Spain. 2Department
of Pathology, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona,
Spain. 3Department of Neurosurgery, Hospital Sant Joan de Déu, Esplugues
de Llobregat, Barcelona, Spain. 4Department of Diagnostic Imaging, Hospital
Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain. 5Department of
Surgery, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona,
Spain. 6Laboratory of Molecular Oncology, Hospital Sant Joan de Déu,
Esplugues de Llobregat, Barcelona, Spain.
Received: 18 March 2020 Accepted: 11 December 2020
References
1. Li FP, Fraumeni JF. Soft-tissue sarcomas, breast cancer, and other
neoplasms. A familial syndrome? Ann Intern Med. 1969;71:747–52.
2. Hisada M, Garber JE, Fung CY, Fraumeni JF Jr, Li FP. Multiple primary
cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst. 1998;90:
606–11.
3. International CPT-SIOP-Registry (www.uke.de/cpt).
4. Lafay-Cousin L, Mabbott DJ, Halliday W, Taylor MD, Tabori U, Kamaly-Asl ID,
Kulkarni AV, Bartels U, Greenberg M, Bouffet E. Use of ifosfamide,
carboplatin, and etoposide chemotherapy in choroid plexus carcinoma. J
Neurosurg Pediatr. 2010;5:615–21.
5. Pritchard-Jones K, Bergeron C, de Camargo B, van den Heuvel-Eibrink MM,
Acha T, Godzinski J, Oldenburger F, Boccon-Gibod L, Leuschner I, Vujanic G,
Sandstedt B, de Kraker J, van Tinteren H, Graf N, SIOP Renal Tumours Study
Group. Omission of doxorubicin from the treatment of stage II-III,
intermediate-risk Wilms’ tumour (SIOP WT 2001): an open-label, non-
inferiority, randomised controlled trial. Lancet. 2015;386:1156–64.
6. Siegfried A, Morin S, Munzer C, et al. A French retrospective study on
clinical outcome in 102 choroid plexus tumors in children. J Neuro-Oncol.
2017;135:151–60.
7. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, et al. Germ
line p53 mutations in a familial syndrome of breast cancer, sarcomas, and
other neoplasms. Science. 1990;250:1233–8.
8. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins,
consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2:
a001008.
9. Zhang Y, Coillie SV, Fang JY, Xu J. Gain of function of mutant p53: R282W
on the peak? Oncogenesis. 2016;5:e196.
10. Xu J, Qian J, Hu Y, Wang J, Zhou X, Chen H, Fang JY. Heterogeneity of Li-
Fraumeni syndrome links to unequal gain-of-function effects of p53
mutations. Sci Rep. 2014;4:4223.
11. Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes:
correlation between tumor type, family structure, and TP53 genotype.
Cancer Res. 2003;63:6643–50.
12. Birch JM, Alston RD, McNally RJQ, Gareth D, Evans R, Kelsey AM, Harris M,
Eden OB, Varley JM. Relative frequency and morphology of cancers in
carriers of germline TP53 mutations. Oncogene. 2001;20:4621–8.
13. Schlegelberger B, Kreipe H, Lehmann U, Steinemann D, Ripperger T,
Göhring G, Thomay K, Rump A, Di Donato N, Suttorp M. A child with Li-
Fraumeni syndrome: modes to inactivate the second allele of TP53in three
different malignancies. Pediatr Blood Cancer. 2015;62:1481–4.
14. Holmfeldt L, Wei L, Diaz-Flores E, et al. The genomic landscape of
hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013;45:242–52.
15. Rausch T, Jones DT, Zapatka M, et al. Genome sequencing of pediatric
medulloblastoma links catastrophic DNA rearrangements with TP53
mutations. Cell. 2012;148:59–71.
16. Lam S, Lin Y, Cherian J, Qadri U, Harris DA, Melkonian S, Jea A. Choroid
plexus tumors in children: a population-based study. Pediatr Neurosurg.
2013;49(6):331–8.
17. Rutherford J, Chu CE, Duddy PM, Charlton RS, Chumas P, Taylor GR, Lu X,
Barnes DM, Camplejohn RS. Investigations on a clinically and functionally
unusual and novel germline p53 mutation. Br J Cancer. 2002;86(10):1592–6.
18. Hu H, Liu J, Liao X, Zhang S, Li H, Lu R, Li X, Lin W, Liu M, Xia Z, Qing G, Li
JD. Genetic and functional analysis of a Li Fraumeni syndrome family in
China. Sci Rep. 2016;6:20221.
19. Jivraj I, Somers GR, Belliveau MJ, Malkin D, DeAngelis DD. Management of
orbital rhabdomyosarcoma in a child with Li-Fraumeni syndrome. J AAPOS
2019;23:182-5.
20. Villani A, Tabori U, Schiffman J, Shlien A, Beyene J, Druker H, Novokmet A,
Finlay J, Malkin D. Biochemical and imaging surveillance in germline TP53
mutation carriers with Li-Fraumeni syndrome: a prospective observational
study. Lancet Oncol. 2011;12:559–67.
21. Mosleh O, Tabori U, Bartels U, Huang A, Schechter T, Bouffet E. Successful
treatment of a recurrent choroid plexus carcinoma with surgery followed by
high-dose chemotherapy and stem cell rescue. Pediatr Hematol Oncol.
2013;30:386–91.
22. Kratz CP, Achatz MI, Brugières L, et al. Cancer screening recommendations
for individuals with Li-Fraumeni syndrome. Clin Cancer Res. 2017;23:e38–45.
23. Villani A, Shore A, Wasserman JD, et al. Biochemical and imaging
surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome:
11 year follow-up of a prospective observational study. Lancet Oncol. 2016;
17:1295–305.
24. Fortuno C, Pesaran T, Dolinsky J, Yussuf A, McGoldrick K, Kho PF, James PA,
Spurdle AB. p53 major hotspot variants are associated with poorer
prognostic features in hereditary cancer patients. Cancer Genet. 2019;235–
236:21–7.
25. Malkin D. Li-Fraumeni Syndrome. Genes Cancer. 2011;2:475–84.
26. Ariffin H, Hainaut P, Puzio-Kuter A, et al. Whole-genome sequencing analysis
of phenotypic heterogeneity and anticipation in Li-Fraumeni cancer
predisposition syndrome. Proc Natl Acad Sci U S A. 2014;111:15497–501.
27. Levine AJ. p53: 800 million years of evolution and 40 years of discovery. Nat
Rev Cancer. 2020; Epub ahead of print.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Cruz et al. Hereditary Cancer in Clinical Practice            (2021) 19:1 Page 6 of 6
